One of the most precious truths in the Bible is that every human is made in the image of God (Genesis 1:27) — meaning that every life from conception to death has undeniable worth and value. This conviction has long led evangelicals to be passionate advocates of pro-life policies and practices.
While the historic Dobbs decision in 2022 clarified there is no constitutional right to abortion, it did not prohibit new legislation by Congress or the states. Today, abortion remains widely available in many states, and access to abortion pills has expanded in recent years.
The National Association of Evangelicals has long advocated for protecting the unborn and lamented the loss of life through abortion on demand. While we give thanks for progress made through decades of advocacy and holistic care, we also grieve the overall increase of abortions since Dobbs, with expanded access to mail-order pills being a significant factor.
What Is Mifepristone?
Mifepristone is one of the two FDA-authorized abortion pills approved through 10 weeks of pregnancy. Until 2023, the FDA required an in-person doctor visit before prescribing mifepristone. In 2023, the Biden administration dropped the in-person doctor visit requirement, and the Trump administration continued the same policy. Mifepristone is now available via telehealth visits and can be dispensed through the mail or approved pharmacies.
Last fall, the FDA approved another generic version of mifepristone, making it even more accessible. According to recent data, abortion pills accounted for 63 percent of all U.S. abortions, and mail-order pills were used in 27 percent of abortions in the first half of 2025. A new Senate report led by Senator Bill Cassidy, M.D., Mifepristone Without Guardrails, frames the trend even more starkly, estimating that online prescriptions accounted for roughly 28 percent of all U.S. abortions in 2025 — about 300,000 — up from just 7 percent in 2022.
The ease with which abortion pills can now be obtained and administered makes pregnant mothers especially vulnerable to coercion or abuse. In some documented cases, partners have put the drug into a woman’s food or drink without her knowledge.
Ongoing Litigation and Legislation
There have been several lawsuits attempting to ban or more tightly regulate access to mifepristone. The NAE joined an amicus brief in one case, FDA v. Alliance for Hippocratic Medicine. So far, these efforts have been unsuccessful.
More recently, the state of Louisiana sued the FDA, arguing that mail-order abortion pills interfere with the state’s ability to regulate abortion. In May, Louisiana asked the Fifth Circuit Court of Appeals to block the FDA rules change while the case was being heard. The Appeals Court ruled in Louisiana’s favor and required mifepristone to be dispensed in person nationwide. In a special order, the U.S. Supreme Court blocked the appeals court ruling, allowing mifepristone to continue to be sent by mail while the case returns to the lower courts. There is no federal law banning access to abortion pills, but several states have total abortion bans or specific restrictions on chemical abortion via telehealth.
The most significant recent development, however, comes from Congress itself with the Mifepristone Without Guardrails report examining the three FDA-approved makers of the drug — Danco Laboratories, GenBioPro and Evita Solutions. The report found that mifepristone manufacturers provided limited information about their operations and played little to no role in monitoring or ensuring that prescribers follow FDA rules.
According to the report:
- Investigators were able to obtain abortion pills online using fake patient information;
- Prescribers are not required to verify a patient’s identity, gestational age or compliance with applicable state law;
- No provider has ever lost FDA certification for violating the requirements;
- The report also raised concerns about opaque overseas manufacturing; and
- The report noted that, since a 2016 regulatory change, nonfatal complications are no longer required to be reported to the FDA.
Crucially, the report’s central recommendation mirrors what the NAE has urged: reinstate the in-person dispensing requirement. The report also calls on the FDA to strengthen its Risk Evaluation and Mitigation Strategy for the drug and urges the Department of Justice to take enforcement action against prescribers who knowingly break the safety rules.
Pathways for Change
The Senate investigation gives fresh, well-documented weight to changes the NAE has supported. We urge President Trump to order the FDA to tighten regulation of mifepristone by:
- Reinstating the in-person dispensing requirement and prohibiting prescriptions from being issued via telehealth appointments; and
- Requiring reporting of adverse side effects and, if warranted by the evidence, considering withdrawing approval of the drug.
Churches can play a vital role by fostering a culture in which mothers and families are supported before, during and after pregnancy. This includes providing compassionate counseling, practical assistance, childcare support and financial assistance. Churches can also partner with and support pregnancy resource centers across the country. For example, Care Net, one of the largest networks of pregnancy centers, reports that its affiliated centers have helped save more than 1 million babies from abortion since 2008.
Resources
- “Sanctity of Life Does Not Depend on Quality of Life,” by Walter Kim in Christianity Today
- Discipleship and Pro Abundant Life Ministry, NAE podcast with Roland Warren